Given that GLUT1, a facilitative glucose transporter, reportedly mediates glucose metabolism in EGFR-mutated NSCLC cells [12], we also determined the expression levels of GLUT1 in these NSCLC cells with and without gefitinib treatment. Here, SLC2A1 is linked to non-small cell lung carcinoma.